These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 17479959)

  • 21. [More about miltefosine in the treatment of mucosal leishmaniasis].
    Bustos MF; Barrio A; Basombrío MÁ
    Medicina (B Aires); 2015; 75(2):131. PubMed ID: 25919882
    [No Abstract]   [Full Text] [Related]  

  • 22. Miltefosine Combined with Intralesional Pentamidine for
    Soto J; Soto P; Ajata A; Rivero D; Luque C; Tintaya C; Berman J
    Am J Trop Med Hyg; 2018 Nov; 99(5):1153-1155. PubMed ID: 30255833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-course of oral miltefosine for treatment of visceral leishmaniasis.
    Sundar S; Makharia A; More DK; Agrawal G; Voss A; Fischer C; Bachmann P; Murray HW
    Clin Infect Dis; 2000 Oct; 31(4):1110-3. PubMed ID: 11049800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of New World cutaneous leishmaniasis with miltefosine.
    Soto J; Berman J
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S34-40. PubMed ID: 16930649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Miltefosine versus meglumine antimoniate in the treatment of mucosal leishmaniasis].
    Garcia Bustos MF; Barrio A; Parodi C; Beckar J; Moreno S; Basombrio MA
    Medicina (B Aires); 2014; 74(5):371-7. PubMed ID: 25347898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.
    Calvopina M; Gomez EA; Sindermann H; Cooper PJ; Hashiguchi Y
    Am J Trop Med Hyg; 2006 Dec; 75(6):1074-7. PubMed ID: 17172368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.
    Soto J; Toledo J; Gutierrez P; Nicholls RS; Padilla J; Engel J; Fischer C; Voss A; Berman J
    Clin Infect Dis; 2001 Oct; 33(7):E57-61. PubMed ID: 11528586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Miltefosine: a new remedy for leishmaniasis].
    Dorlo TP; Eggelte TA; Beijnen JH; de Vries PJ
    Ned Tijdschr Geneeskd; 2006 Dec; 150(49):2697-701. PubMed ID: 17194005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful treatment of a married couple for American leishmaniasis with miltefosine.
    Wöhrl S; Schnedl J; Auer H; Walochnik J; Stingl G; Geusau A
    J Eur Acad Dermatol Venereol; 2008 Feb; 22(2):258-9. PubMed ID: 18211436
    [No Abstract]   [Full Text] [Related]  

  • 30. [Miltefosine or meglumine antimoniate in leishmaniasis].
    Joob B; Wiwanitkit V
    Medicina (B Aires); 2015; 75(2):130-1. PubMed ID: 25919881
    [No Abstract]   [Full Text] [Related]  

  • 31. Case Report: Successful Treatment with Miltefosine of Severe New World Mucosal Leishmaniasis Caused by
    Calvopina M; Jijon S; Serrano E; Kato H
    Am J Trop Med Hyg; 2020 Aug; 103(2):752-755. PubMed ID: 32524951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral miltefosine in the treatment of kala-azar.
    Mohan A; Seth S
    Natl Med J India; 2000; 13(4):202-3. PubMed ID: 11002688
    [No Abstract]   [Full Text] [Related]  

  • 33. Mucosal Leishmania infantum infection.
    Richter J; Hanus I; Häussinger D; Löscher T; Harms G
    Parasitol Res; 2011 Sep; 109(3):959-62. PubMed ID: 21499751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Miltefosine (Impavido): the first oral treatment against leishmaniasis.
    Sindermann H; Croft SL; Engel KR; Bommer W; Eibl HJ; Unger C; Engel J
    Med Microbiol Immunol; 2004 Nov; 193(4):173-80. PubMed ID: 14513375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis.
    Bezerra-Souza A; Yamamoto ES; Laurenti MD; Ribeiro SP; Passero LF
    Parasitol Int; 2016 Dec; 65(6 Pt A):702-707. PubMed ID: 27546158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Miltefosine for the treatment of cutaneous leishmaniasis-A pilot study from Ethiopia.
    van Henten S; Tesfaye AB; Abdela SG; Tilahun F; Fikre H; Buyze J; Kassa M; Cnops L; Pareyn M; Mohammed R; Vogt F; Diro E; van Griensven J
    PLoS Negl Trop Dis; 2021 May; 15(5):e0009460. PubMed ID: 34048461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo activity of perifosine against Leishmania amazonensis.
    Cabrera-Serra MG; Valladares B; Piñero JE
    Acta Trop; 2008 Oct; 108(1):20-5. PubMed ID: 18801328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.
    Marques N; Sá R; Coelho F; Oliveira J; Saraiva Da Cunha J; Meliço-Silvestre A
    Scand J Infect Dis; 2008; 40(6-7):523-6. PubMed ID: 18584541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparative study between oral miltefosine and parenteral N-metil glucamine antimoniate for the treatment of experimental leishmaniasis caused Leishmania (Leishmania) amazonensis].
    Costa Filho AV; Lucas IC; Sampaio RN
    Rev Soc Bras Med Trop; 2008; 41(4):424-7. PubMed ID: 18853022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis: Follow-Up.
    Coelho AC; Trinconi CT; Costa CH; Uliana SR
    PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004720. PubMed ID: 27416021
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.